Ve-cadherin and vegfr-2 antagonists for therapeutic modulation of angiogenesis

A method of modulating angiogenesis in an animal in need thereof, while reducing toxicity, comprising:

• administering an antagonist of vascular endothelial cadherin;
• and
• administering an antagonist of vascular endothelial growth factor receptor.

A method of treating a disease associated with pathological angiogenesis, comprising:

• administering an antagonist of vascular endothelial cadherin;
• and
• administering an antagonist of vascular endothelial growth factor receptor.

A method of treating, with reduced toxicity, a disease associated with pathological vascular permeability, comprising:

• administering an antagonist of vascular endothelial cadherin;
• and
• administering an antagonist of vascular endothelial growth factor receptor.

A composition for modulating angiogenesis in an animal in need thereof, while reducing toxicity, comprising:

• an antagonist of a vascular endothelial cadherin;
• and
• an antagonist of a vascular endothelial growth factor receptor.

A method of modulating angiogenesis in an animal in need thereof, while reducing toxicity, comprising:

• administering p1C11;
• and
• administering BV13.

A method of inhibiting the growth of a solid tumor, comprising:

• administering an antagonist of a vascular endothelial cadherin;
• and
• administering an antagonist of a vascular endothelial growth factor receptor, wherein the development of pathologically increased vascular permeability is inhibited.

A method of inhibiting pathologically increased vascular permeability to an animal in need thereof, comprising:

• administering an antagonist of a vascular endothelial growth factor receptor.

A composition for inhibiting pathologically increased vascular permeability in an animal in need thereof, comprising:

• an antagonist of a vascular endothelial growth factor receptor.